This inventor holds 2 USPTO granted patents, plus 2 CIPO patents and 2 EPO patents. Top assignees: Bebetter Med Inc., Guangzhou Bebetter Medicine Technology Co., Ltd.. Active years: 2019-2022.
Company Filing History:
1 out of 2 
1 out of 1 Years Active: 2019-2022
Title: Weicai Xue: Innovator in Medicinal Chemistry
Introduction
Weicai Xue is a notable inventor based in Guangdong, China. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds for treating various types of cancer. With a total of 2 patents, his work focuses on innovative solutions for complex medical challenges.
Latest Patents
Weicai Xue's latest patents include a 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, which has shown promise in the preparation of anti-tumor drugs. This compound selectively suppresses the activity of mutant epidermal growth factor receptors (EGFR), including the T790M mutation, which is prevalent in non-small cell lung cancer (NSCLC). His second patent involves a pyrimidine or pyridopyridone compound that selectively targets cyclin-dependent kinases (Cdks) CDK4 and CDK6, offering potential treatments for diseases caused by cell cycle control disorders.
Career Highlights
Throughout his career, Weicai Xue has worked with several companies, including Guangzhou Bebetter Medicine Technology Co., Ltd. and Bebetter Med Inc. His expertise in medicinal chemistry has positioned him as a key player in the development of innovative therapeutic solutions.
Collaborations
Weicai Xue has collaborated with notable colleagues such as Yuanhui Qing and Yanyan Wang. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.
Conclusion
Weicai Xue's contributions to medicinal chemistry highlight his innovative spirit and dedication to improving cancer treatment options. His patents reflect a commitment to addressing critical health challenges through scientific research and development.